Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin versus best available therapy for choroidal neovascularisation secondary to age-related macular degeneration
ISRCTN83325075Phase 3Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in age-related macular degeneration (AMD) and Subretinal neovascularization (4 arms), sponsored by Moorfields Eye Hospital. Primary endpoint: Gain of 15 letters or more in best corrected visual acuity at 12 months. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on ISRCTN83325075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83325075.